Show simple item record

dc.contributor.authorMagan, Natisha
dc.date.accessioned2010-05-04T20:26:46Z
dc.date.availableNO_RESTRICTIONen_US
dc.date.available2010-05-04T20:26:46Z
dc.date.issued2009
dc.identifier.urihttp://hdl.handle.net/10179/1292
dc.description.abstractAmong women in the 45 to 64 age group, over half of the recorded deaths are from cancer, breast cancer being the most common. Just over 30% off all deaths in New Zealand women is caused by breast cancer. Treatment of cancer is difficult, not only due to the physiological and immunological similarities between a cancer cell and a normal cell, but also due to the high cardiotoxicity of many treatments, and also the problems related with the development of resistance. Approximately 40% of the cancer cells treated with the chemotherapy drug doxorubicin will become resistant to treatment. Drug efficacy is strongly associated with the proliferation status of a cell, as cancer cells divide rapidly, this can often be the defining factor between effective treatments or the development of resistance. Central to this proliferation status is an enzyme known as topoisomerase IIa. This essential enzyme is expressed in all cells and is required to relieve the torsional stress in DNA that is created during normal cellular processes. A number of commonly used anti-cancer drugs have been found to target topoisomerase IIa in cancer cells and significantly, during the development of drug resistance levels of topoisomerase IIa enzyme have been found to be reduced in some cell lines and tumours. There are a number of factors that can modulate the amount of topoisomerase IIa enzyme found in a cell, and one of the ways to understand this is to examine the regulation of the topoisomerase IIa gene, most importantly the proteins that interact with the promoter region to direct transcription. The human topoisomerase IIa promoter has been found to be regulated by a number of transcription factors that can bind to their cognate sequences. The introduction of mutations within specific sequences of the topoisomerase IIa promoter has enabled the identification of a key regulatory region within the promoter, a sequence of DNA that encompasses both the ICB1 and GC1 regulatory elements. Transcription factor NF-Y is found to bind to ICB1 element, whereas transcription factors Sp1 and Sp3 have been found to associate with the GC element. However this region of the promoter was also found to bind a fourth uncharacterised component. This research aims to further define the protein components that are found to bind to this important ICB1/GC1 regulatory region and distinguish the protein-protein and protein-DNA interactions that are important for the regulation of the human topoisomerase IIa promoter.en_US
dc.language.isoenen_US
dc.publisherMassey Universityen_US
dc.rightsThe Authoren_US
dc.subjectHuman topoisomerase IIα promoteren_US
dc.subjectHuman topoisomerase IIalpha promotoeren_US
dc.subject.otherFields of Research::270000 Biological Sciences::270100 Biochemistry and Cell Biologyen_US
dc.titleProtein interactions at the human topoisomerase II[alpha] promoter : a thesis presented to Massey University in partial fulfilment of the requirement for the degree Doctor of Philosophy in Biochemistryen_US
dc.typeThesisen_US
thesis.degree.disciplineBiochemistryen_US
thesis.degree.grantorMassey Universityen_US
thesis.degree.levelDoctoralen_US
thesis.degree.levelDoctoralen
thesis.degree.nameDoctor of Philosophy (Ph.D.)en_US


Files in this item

Icon
Icon

This item appears in the following Collection(s)

Show simple item record